RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabin...
Q1 2026
May 14, 2026
FY 2025
Mar 30, 2026
Q4 2025
Q3 2025
Nov 13, 2025
Q2 2025
Aug 14, 2025
